Overview of safety of non-biologic and biologic DMARDs

Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited numbers of subjects and are primarily powered for efficacy. The most useful post-marketing data come from large national registries, such as...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Rheumatology (Oxford, England) England), 2012-12, Vol.51 Suppl 6 (suppl 6), p.vi37-vi43
1. Verfasser:	Ruderman, Eric M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biological Products - adverse effects Biological Products - therapeutic use Clinical trials Humans Mycobacterium Opportunistic Infections - epidemiology Registries Risk Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!